# Examining the effect of intermittent cycling throughout a 3-h period on peripheral blood concentrations of haemopoietic stem and progenitor cells and cytolytic natural killer cells

**Authors:** Phoebe A. Cox, Fendi Pradana, Ella Noble, Samuel J. E. Lucas, Guy Pratt, Mark T. Drayson, Kevin Amin, Francesca A. M. Kinsella, Alex J. Wadley

PMC · DOI: 10.1186/s13287-025-04261-1 · 2025-03-28

## TL;DR

This study examines how intermittent cycling during a 3-hour period affects the levels of blood stem and immune cells, finding that moderate-intensity cycling boosts certain immune cells but not stem cells.

## Contribution

The study evaluates feasible cycling protocols during stem cell collection to enhance immune cell mobilization.

## Key findings

- Moderate-intensity interval exercise (MIIE) increased CD56dim NK cell concentrations more than rest.
- High-intensity interval exercise (HIIE) showed a significantly greater area under the curve for CD56dim NK cells compared to rest.
- Neither MIIE nor HIIE reliably increased haemopoietic stem and progenitor cell (HSPC) levels compared to rest.

## Abstract

Peripheral blood stem cell (PBSC) donation is the primary procedure used to collect haemopoietic stem and progenitor cells (HSPCs) for haemopoietic stem cell transplants (HSCT), however there is a clinical need to reduce collection times and achieve sufficient HSPC doses for successful engraftment. Short bouts of interval cycling transiently enrich peripheral blood with HSPCs and cytolytic natural killer (CD56dim NK) cells, which predict engraftment success and prevent post-transplant complications respectively. Despite this, feasible protocols for use during PBSC collections (≈ 3 h) have yet to be evaluated.

In a randomised crossover design, 18 adults (9 young: 22.7 ± 3.2 years, 9 older: 65.2 ± 12.9 years) completed 3 × 3-h trials: high-intensity interval exercise (HIIE, 9 × 2-min cycling at 80–85% heart rate (HR)max/9 × 18 min rest), moderate-intensity interval exercise (MIIE, 9 × 4-min cycling at 65–70% HRmax/9 × 16 min rest) and REST (180 min). Immune cell subsets, including HSPCs and CD56dim NK concentrations (cells/µL) were determined across 18 timepoints and area under the curve (AUC, cells/µL x minutes) and total cell dose (cells/kg) were estimated.

By design, MIIE elicited lower average and peak HR and rating of perceived exertion than HIIE and was reported as more enjoyable. All cell subset concentrations increased following each interval of MIIE and HIIE. Across all participants, the estimated cell dose of total lymphocytes, monocytes, T cells, CD56bright and CD56dim NK was greater in MIIE and HIIE versus REST (p < 0.03), but there were no differences between MIIE and HIIE. The magnitude of change versus REST was greatest for CD56dim NK versus all cell subsets, and AUC was significantly greater in HIIE versus REST for this cell type only (p < 0.0001). There were no statistically significant differences in HSPC AUC (p = 0.77) or cell dose (p = 0.0732) in MIIE and HIIE versus REST. Age did not predict any changes across trials or timepoints for any cell type.

Persistent mobilisation of peripheral blood immune cells throughout 3 h of MIIE and HIIE evoked sustained numbers of CD56dim NK cells, but there was no reliable difference in HSPCs compared to a time-matched period of rest.

The online version contains supplementary material available at 10.1186/s13287-025-04261-1.

## Full-text entities

- **Genes:** FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, PSMA7 (proteasome 20S subunit alpha 7) [NCBI Gene 5688] {aka C6, HEL-S-276, HSPC, RC6-1, XAPC7}, PTK2 (protein tyrosine kinase 2) [NCBI Gene 5747] {aka FADK, FADK 1, FAK, FAK1, FRNK, PPP1R71}, RNF130 (ring finger protein 130) [NCBI Gene 55819] {aka G1RP, G1RZFP, GOLIATH, GP}, MT1E (metallothionein 1E) [NCBI Gene 4493] {aka MT-1E, MT-IE, MT1, MTD}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, REST (RE1 silencing transcription factor) [NCBI Gene 5978] {aka DFNA27, GINGF5, HGF5, NRSF, WT6, XBR}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, CSF3 (colony stimulating factor 3) [NCBI Gene 1440] {aka C17orf33, CSF3OS, GCSF}, CD34 (CD34 molecule) [NCBI Gene 947], ADRB2 (adrenoceptor beta 2) [NCBI Gene 154] {aka ADRB2R, ADRBR, ARB2, B2AR, BAR, BETA2AR}
- **Diseases:** irregular heart rhythms (MESH:D008599), bone/joint pain (MESH:D018771), cytotoxic (MESH:D064420), infection (MESH:D007239), daytime dysfunction (MESH:D006970), HIIE (MESH:D000092202), Graft versus Host Disease (MESH:D006086), Anxiety (MESH:D001007), cancer (MESH:D009369), cardiovascular, metabolic, respiratory, or neurological disease (MESH:D012140), hypotension (MESH:D007022), OA (MESH:D010003), Fatigue (MESH:D005221), cardiac arrhythmias (MESH:D001145), nausea (MESH:D009325)
- **Chemicals:** carbohydrate (MESH:D002241), caffeine (MESH:D002110), 7-amino-actinmyosin D (-), Plerixafor (MESH:C088327), alcohol (MESH:D000438), steroids (MESH:D013256), D-PBS (MESH:C012939), sodium chloride (MESH:D012965), Sodium Azide (MESH:D019810), water (MESH:D014867)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11951530/full.md

---
Source: https://tomesphere.com/paper/PMC11951530